Literature DB >> 308618

Serum 1,25-dihydroxyvitamin D levels in normal subjects and in patients with hereditary rickets or bone disease.

C R Scriver, T M Reade, H F DeLuca, A J Hamstra.   

Abstract

The serum concentration of 1,25-dihydroxylvitamin D (1,25-[OH]2D) in normal children and in children with inherited diseases of bone was compared by use of a competitive binding assay. Observed values were: in 12 normal children and adolescents, 37.1 +/- 1.9 pg per milliliter (mean +/- S.D.); in 14 patients with X-linked hypophosphatemic rickets treated with vitamin D2 and phosphate supplements, 15.6 +/- 7.8 (P less than 0.01 versus control); in six patients with autosomal recessive vitamin D dependency treated with vitamin D2, 9.5 +/- 2.9 (P less than 0.01 versus control); and in four untreated patients with autosomal dominant hypophosphatemic (non-rachitic) bone disease, 30.2 +/- 6.3 (not significantly different from the controls). The difference in bone disease between X-linked hypophosphatemia (severe) and hypophosphatemic bone disease (mild) at comparable low serum levels of phosphate implies that 1,25-(OH)2D and phosphate may have independent roles in the pathogenesis of defective bone mineralization.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 308618     DOI: 10.1056/NEJM197811022991803

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  41 in total

1.  Osteomalacia and altered magnesium metabolism in the X-linked hypophosphatemic mouse.

Authors:  R A Meyer; J Jowsey; M H Meyer
Journal:  Calcif Tissue Int       Date:  1979-03-13       Impact factor: 4.333

Review 2.  Molecular genetics of mineral metabolic disorders.

Authors:  R V Thakker
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

3.  Phosphatonin washout in Hyp mice proximal tubules: evidence for posttranscriptional regulation.

Authors:  Michel Baum; Orson W Moe; Jianning Zhang; Vangipuram Dwarakanath; Raymond Quigley
Journal:  Am J Physiol Renal Physiol       Date:  2004-09-28

4.  X linked hypophosphataemia: treatment, height gain, and nephrocalcinosis.

Authors:  G S Reusz; P F Hoyer; M Lucas; H P Krohn; J H Ehrich; J Brodehl
Journal:  Arch Dis Child       Date:  1990-10       Impact factor: 3.791

Review 5.  Role of prostaglandins in the pathogenesis of X-linked hypophosphatemia.

Authors:  Michel Baum; Ashu Syal; Raymond Quigley; Mouin Seikaly
Journal:  Pediatr Nephrol       Date:  2006-05-24       Impact factor: 3.714

6.  Parathyroid hormone activation of the 25-hydroxyvitamin D3-1alpha-hydroxylase gene promoter.

Authors:  H L Brenza; C Kimmel-Jehan; F Jehan; T Shinki; S Wakino; H Anazawa; T Suda; H F DeLuca
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

Review 7.  Cytochrome P450-mediated metabolism of vitamin D.

Authors:  Glenville Jones; David E Prosser; Martin Kaufmann
Journal:  J Lipid Res       Date:  2013-04-06       Impact factor: 5.922

8.  Increased renal catabolism of 1,25-dihydroxyvitamin D3 in murine X-linked hypophosphatemic rickets.

Authors:  H S Tenenhouse; A Yip; G Jones
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

Review 9.  Vitamin D/dietary calcium deficiency rickets and pseudo-vitamin D deficiency rickets.

Authors:  Francis H Glorieux; John M Pettifor
Journal:  Bonekey Rep       Date:  2014-03-19

10.  Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia.

Authors:  M K Drezner; K W Lyles; M R Haussler; J M Harrelson
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.